311 related articles for article (PubMed ID: 21114393)
21. Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Marchetti F; Candusso M; Faraguna D; Assael BM
Lancet; 2002 Feb; 359(9306):626-7. PubMed ID: 11867141
[No Abstract] [Full Text] [Related]
22. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.
Saiman L
Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923
[TBL] [Abstract][Full Text] [Related]
23. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
24. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
[TBL] [Abstract][Full Text] [Related]
25. Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.
Schultz AN; Høiby N; Nielsen XC; Pressler T; Dalhoff K; Duno M; Buchard A; Johansen HK; Wang H; Dalbøge CS
Pediatr Pulmonol; 2017 Mar; 52(3):319-323. PubMed ID: 28221736
[TBL] [Abstract][Full Text] [Related]
26. Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Ang JY; Abdel-Haq N; Zhu F; Thabit AK; Nicolau DP; Satlin MJ; van Duin D
Antimicrob Agents Chemother; 2016 Oct; 60(10):5627-30. PubMed ID: 27664282
[TBL] [Abstract][Full Text] [Related]
27. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
[TBL] [Abstract][Full Text] [Related]
28. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Ciofu O; Giwercman B; Pedersen SS; Høiby N
APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
[TBL] [Abstract][Full Text] [Related]
29. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
[No Abstract] [Full Text] [Related]
30. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
Hata JS; Fick RB
Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
[TBL] [Abstract][Full Text] [Related]
31. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
32. [Anti-Pseudomonas aeruginosa (Pa) antibiotic therapy and cystic fibrosis].
Bellon G; Gilly R
Rev Mal Respir; 1991; 8(2):263. PubMed ID: 1907014
[No Abstract] [Full Text] [Related]
33. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Farinde A
Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
[No Abstract] [Full Text] [Related]
34. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
35. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
[TBL] [Abstract][Full Text] [Related]
36. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
Lahiri T
Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
[TBL] [Abstract][Full Text] [Related]
37. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
[TBL] [Abstract][Full Text] [Related]
38. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
Kernen Y; Sauty A; Roulet M
Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
[TBL] [Abstract][Full Text] [Related]
39. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
Saiman L; Cohen MB
Arch Pediatr Adolesc Med; 2011 Sep; 165(9):867-8. PubMed ID: 21893653
[No Abstract] [Full Text] [Related]
40. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
Bosso JA; Mauldin PD; Steed LL
Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
